Maxim analyst Jason McCarthy initiated coverage of Lipella Pharmaceuticals with a Buy rating and $2 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals to publish abstract on preclinical support for LP-50
- Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
- Lipella Pharmaceuticals announces FDA Type C meeting for LP-10
- Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
- Lipella Pharmaceuticals announces FDA clearance of IND for LP-410